Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Inmune BioINMB | Open-market buy | 24/09/30 | 24/09/30 | 10,000 sh | $5.29 | $52,900 | +0.8% | |
Inmune BioINMB | Open-market buy | 24/09/12 | 24/09/16 | 7,690 sh | $6.38 | $49,062.2 | +0.6% | |
Raymond Joseph TesiPresident and CEO | Inmune BioINMB | Open-market buy | 24/09/12 | 24/09/16 | 15,380 sh | $6.38 | $98,124.4 | +1.0% |
Scott JudaDirector | Inmune BioINMB | Open-market buy | 24/06/25 | 24/06/26 | 5,000 sh | $7.27 | $36,350 | +7.5% |
David J. MossCFO, Treasurer & Secretary | Inmune BioINMB | Open-market buyAmendment | 24/04/19 | 24/04/24 | 18,028 sh | $8.32 | $149,992.96 | +1.4% |
Mark William LowdellChief Scientific Officer | Inmune BioINMB | Open-market buyAmendment | 24/04/19 | 24/04/24 | 14,423 sh | $8.32 | $119,999.36 | +1.0% |
Scott JudaDirector | Inmune BioINMB | Open-market buyAmendment | 24/04/19 | 24/04/24 | 29,603 sh | $8.32 | $246,296.96 | +80.0% |
Raymond Joseph TesiPresident and CEO | Inmune BioINMB | Open-market buyAmendment | 24/04/19 | 24/04/24 | 18,028 sh | $8.32 | $149,992.96 | +1.2% |
Scott JudaDirector | Inmune BioINMB | Open-market buy | 23/11/10 | 23/11/13 | 7,000 sh | $6.95 | $48,650 | +23.3% |
Timothy J. SchroederDirector | Inmune BioINMB | Open-market sale10b5-1 plan | 23/07/12 | 23/07/14 | 10,000 sh | $11.01 | $110,100 | −10.8% |
David J. MossCFO, Treasurer & Secretary | Inmune BioINMB | Open-market buy | 23/03/17 | 23/03/20 | 2,500 sh | $6.43 | $16,075 | +0.2% |